Evercore ISI added TransMedics (TMDX) to the firm’s “Tactical Underperform” list, telling investors that flight tracking suggests Q3 revenue could miss expecations by a few percent. The firm also sees industry reforms leading to potential near-term volatility. Evercore has an Outperform rating and $155 price target on TransMedics shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group Acquires Aircraft for Organ Transport
- TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales Fluctuations
- TransMedics, Mercedes-Benz partner on organ transportation across Italy
- Hold Rating for TransMedics Group Amid Uncertain Transplant Volume and Sales Projections
- TransMedics teams with Mercedes-Benz Group on organ transportation across Italy